Illumina (ILMN) - FREE Research Report

Walt David R who is Director at Illumina sold 5,000 shares at $93.02 on Nov. 1, 2013. Following this transaction, the Director owned 911,488 shares meaning that the stake was reduced by 0.55% with the 5,000 share transaction.

The shares most recently traded at $95.65, up $2.63, or 2.74% since the insider transaction. Historical insider transactions for Illumina go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 26,627
  • 24-Week # shares sold: 58,096

The average volume for Illumina has been 989,600 shares per day over the past 30 days. Illumina has a market cap of $11.7 billion and is part of the health care sector and drugs industry. Shares are up 68.21% year to date as of the close of trading on Friday.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company has a P/E ratio of 70.8. Currently there are 9 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE

TheStreet Quant Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, increase in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Illumina Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

McCormick in $4.2 Billion Play for Reckitt Benckiser's Food Division

Reckitt Wrecked By Petya Virus

Reckitt Benckiser Says Petya Cyber Attack Will Slam Q2 Revenues

Reckitt to Close $18 Billion Mead Johnson Takeover Deal June 15